
Episode 16: Part 1 - Eczema Therapeutics
07/05/24 • 39 min
In this episode our host Dr Sarah Drummond speaks with Professor Catherine Smith and Dr Andrew Pink about eczema therapeutics:
• Where conventional systemic agents fit within the evolving landscape of eczema therapeutics.
• The biologic agents licensed for use in eczema including their mechanism of action, monitoring requirements and potential side effects.
Recorded: 19 March 2024
For more information, visit: www.stjohnsdermacademy.com/podcasts
Disclaimer: The information on our podcasts is based on the latest evidence and expert opinion at the time of recording. The information is for general purposes only and we cannot offer advice for specific patients. Equally, this information is geared towards healthcare professionals. Any member of the public or patients listening should not use this as advice to treat their own condition or others and should consult their own physician for any medical needs they may have.
In this episode our host Dr Sarah Drummond speaks with Professor Catherine Smith and Dr Andrew Pink about eczema therapeutics:
• Where conventional systemic agents fit within the evolving landscape of eczema therapeutics.
• The biologic agents licensed for use in eczema including their mechanism of action, monitoring requirements and potential side effects.
Recorded: 19 March 2024
For more information, visit: www.stjohnsdermacademy.com/podcasts
Disclaimer: The information on our podcasts is based on the latest evidence and expert opinion at the time of recording. The information is for general purposes only and we cannot offer advice for specific patients. Equally, this information is geared towards healthcare professionals. Any member of the public or patients listening should not use this as advice to treat their own condition or others and should consult their own physician for any medical needs they may have.
Previous Episode

Episode 14: Part 1: Immunobullous disorder - Bullous pemphigoid
In this episode our host Dr Sarah Drummond speaks with Dr Thomas Tull about bullous pemphigoid:
• The clinical features and risk factors for developing bullous pemphigoid
• How to differentiate bullous pemphigoid from other subepidermal blistering disorders
• Management of bullous pemphigoid including:
o Preferred first and second line agents
o How and when to reduce treatment
o What to do in severe and refractory cases
Resources and further reading:
• European guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology, 2022 (updated) (https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.18220)
• British Association of Dermatologists’ guidelines for the management of bullous pemphigoid, 2012 (https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.12072)
Disclosure:
Dr. Tull provides consultancy services for Argenx who market Efgartigimod, which has been referenced in Part 1 and 2 of this series.
Recorded date: 26 January 2024
Please visit our website https://www.stjohnsdermacademy.com/podcasts for episode notes and references.
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/st-johns-dermacademy-podcast-506969/episode-16-part-1-eczema-therapeutics-66615357"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to episode 16: part 1 - eczema therapeutics on goodpods" style="width: 225px" /> </a>
Copy